Silver Book Fact

For beneficiaries with wet age-related macular degeneration (AMD), annual Medicare part B payments for vision care increased from $1,504 per beneficiary in 1994 to $3,263 in 2006–due in large part to anti-VEGF treatments.

Day S, Acquah K, Lee P, Mruthyunjaya P, et al. Medicare Costs for Neovascular Age-Related Macular Degeneration, 1994-2007. Ophthalmol. 2011; 152(6): 1014-20. http://www.ajo.com/article/S0002-9394%2811%2900410-7/abstract

Reference

Title
Medicare Costs for Neovascular Age-Related Macular Degeneration, 1994-2007
Publication
Ophthalmol
Publication Date
2011
Authors
Day S, Acquah K, Lee P, Mruthyunjaya P, et al.
Volume & Issue
Volume 152, Issue 6
Pages
1014-20
URL
Read Full Resource

Categories

  • Cost of Disease
  • Economic Burden

Related Facts

  • Of the study participants in the Los Angeles Latino Eye Study (LALES) who had open-angle glaucoma, 75% were previously undiagnosed.  
  • Blindness due to glaucoma
    Three out of four Americans that are legally blind due to glaucoma are over 65.  
  • The average cost in 2004 per glaucoma patient age 40 to 64 using outpatient services was $276. The average cost per patient 54 years and older was $254.  
  • Medicare beneficiaries with vision loss from glaucoma are significantly more likely to be placed in a nursing home and to develop depression, 67% more likely to fracture a femur, and…  
  • The number of cases of visual impairment and blindness from age-related macular degeneration (AMD0 is projected to increase from 620,000 in 2010 to 1.6 million in 2050–assuming no treatments.